Evidence map›Paper›PMID 35549890›Full record

ArticleBMC genomics2022

Characterization of qnrB-carrying plasmids from ESBL- and non-ESBL-producing Escherichia coli.

Katharina Juraschek, Janina Malekzadah, Burkhard Malorny, Annemarie Käsbohrer, Stefan Schwarz, Diana Meemken, Jens Andre Hammerl

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Green and chemical synthesis of CuMicrobiology spectrum · 2026
    Article
  7. Population-based Study of Carbapenem-resistantOpen forum infectious diseases · 2026
    Article
  8. Tracking ESBL-ProducingVeterinary sciences · 2026
    Article
  9. Article
  10. Article
  11. First national study on genomic profiling ofEnvironmental challenges (Amsterdam, Netherlands) · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. UropathogenicCurrent issues in molecular biology · 2024
    Article
  19. ChromosomalMicrobiology resource announcements · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Katharina JuraschekDepartment Biological Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn Str. 8-10, 10589, Berlin, Germany. kajuraschek@hotmail.de.
Janina MalekzadahDepartment Biological Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn Str. 8-10, 10589, Berlin, Germany.
Burkhard MalornyDepartment Biological Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn Str. 8-10, 10589, Berlin, Germany.
Annemarie KäsbohrerDepartment Biological Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn Str. 8-10, 10589, Berlin, Germany.
Stefan SchwarzInstitute of Microbiology and Epizootics, Department of Veterinary Medicine, Veterinary Centre for Resistance Research (TZR), Freie Universität Berlin, 14163, Berlin, Germany.
Diana MeemkenVeterinary Centre for Resistance Research (TZR), Freie Universität Berlin, Robert-von-Ostertag-Str. 8, 14163 Berlin, Germany.
Jens Andre HammerlDepartment Biological Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn Str. 8-10, 10589, Berlin, Germany. Jens-Andre.Hammerl@bfr.bund.de.
Federal Institute for Risk Assessment · DEFreie Universität Berlin · DEUniversity of Veterinary Medicine Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEscherichia coli carrying clinically important antimicrobial resistances [i.e., against extended-spectrum-beta-lactamases (ESBL)] are of high concern for human health and are increasingly detected worldwide. Worryingly, they are often identified as multidrug-resistant (MDR) isolates, frequently including resistances against quinolones/fluoroquinolones.

resultsHere, the occurrence and genetic basis of the fluoroquinolone resistance enhancing determinant qnrB in ESBL-/non-ESBL-producing E. coli was investigated. Overall, 33 qnrB-carrying isolates out of the annual German antimicrobial resistance (AMR) monitoring on commensal E. coli (incl. ESBL-/AmpC-producing E. coli) recovered from food and livestock between 2013 and 2018 were analysed in detail. Whole-genome sequencing, bioinformatics analyses and transferability evaluation was conducted to characterise the prevailing qnrB-associated plasmids. Furthermore, predominant qnrB-carrying plasmid-types were subjected to in silico genome reconstruction analysis. In general, the qnrB-carrying E. coli were found to be highly heterogenic in their multilocus sequence types (STs) and their phenotypic resistance profiles. Most of them appeared to be MDR and exhibited resistances against up to ten antimicrobials of different classes. With respect to qnrB-carrying plasmids, we found qnrB19 located on small Col440I plasmids to be most widespread among ESBL-producing E. coli from German livestock and food. This Col440I plasmid-type was found to be highly conserved by exhibiting qnrB19, a pspF operon and different genes of unassigned function. Furthermore, we detected plasmids of the incompatibility groups IncN and IncH as carriers of qnrB. All qnrB-carrying plasmids also exhibited virulence factors and various insertion sequences (IS). The majority of the qnrB-carrying plasmids were determined to be self-transmissible, indicating their possible contribution to the spread of resistances against (fluoro)quinolones and other antimicrobials.

conclusionIn this study, a diversity of different plasmid types carrying qnrB alone or in combination with other resistance determinants (i.e., beta-lactamase genes) were found. The spread of these plasmids, especially those carrying antimicrobial resistance genes against highest priority critically important antimicrobial agents, is highly unfavourable and can pose a threat for public health. Therefore, the dissemination pathways and evolution of these plasmids need to be further monitored.

Indexed as

Escherichia coli InfectionsEscherichia coli ProteinsQuinolonesAnimalsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCattleEscherichia coliFecesHumansMeatMicrobial Sensitivity TestsPlasmidsPoultryPoultry ProductsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesEscherichia coli ProteinsPspF protein, E coliQuinolonesTrans-ActivatorsE. coliFluoroquinoloneInc-groupPlasmidsqnrB

Identifiers

PMID35549890
PMCPMC9101827
OpenAlexW4280599396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.